Most employers do not yet have a fully formed cardiometabolic strategy. Instead, they are beginning to assemble a playbook—often in response to GLP-1 pressure, rising costs, and growing employee demand. This session takes an honest look at what employers are starting to put in place, where fragmentation persists, which tools belong in their long-term architecture, and which early decisions matter most as organizations move from reactive programs toward a more coherent approach to cardiometabolic risk.